Nishikawa K, et al. - The goal of this research was to determine the efficacy and safety of capecitabine plus cisplatin (XP) treatment for advanced gastric cancer (AGC) in patients who relapsed within 6 months after S-1-based chemotherapy. XP was safe and effective in patients with early relapse after S-1 adjuvant chemotherapy for curatively resected gastric cancers. Furthermore, it was concluded that XP could serve as a good option for the treatment of patients after early failure after adjuvant S-1.